Last edition
News about "Novartis Canada"
Novartis Wins Health Canada Approval for RHAPSIDO in CSU
Novartis has received Health Canada approval for RHAPSIDO (remibrutinib), a new oral treatment for adults with Chronic Spontaneous Urticari (CSU).
Novartis Canada | 29/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members